Former executive, Linda Yaccarino, transitions to a new role outside of Elon Musk's organization, X.
Linda Yaccarino Appointed as CEO of Telehealth Company eMed
Linda Yaccarino, the former CEO of Elon Musk-owned social media platform X, has made a significant shift in her career by joining eMed, a Miami-based telehealth company. Yaccarino, who has a background primarily in marketing, advertising, and media, brings her expertise to eMed as they aim to make chronic care accessible through a digital-first experience.
Yaccarino joined eMed in August 2025, after spending about two years at X. During her tenure at X, she led the company through a challenging period of advertiser pullback and implemented marketplace and advertising transformations. Before that, she spent over a decade at NBCUniversal, where she was chairman of global advertising and partnerships, modernizing its global advertising business and building major brand partnerships.
At eMed, Yaccarino's primary role is to accelerate the company's mission of delivering chronic care in a digital-first experience, especially in managing obesity and diabetes treatments through GLP-1 drugs. eMed specializes in dispensing GLP-1 medications such as Wegovy and Ozempic. The company was founded in 2020, initially offering Covid tests and services, but has since pivoted to weight loss drugs.
Yaccarino's appointment to eMed represents a shift into digital health, leveraging her leadership experience to combine technology, lifestyle, and data in a new powerful way through digital channels. Her experience in negotiating partnerships and leading transformational changes in complex markets is seen as critical for expanding eMed’s services nationally and globally in the population health management field.
However, Yaccarino's departure from X was not without controversy. A day before her departure, X's Grok chatbot began pushing antisemitic tropes in responses to users. During her tenure, Yaccarin faced repeated public relations crises, including scrutiny over hateful content, false claims, and ads appearing alongside pro-Nazi content. Some brands pulled their spending, leading to a lawsuit by Yaccarino-led X against an advertising industry group. The industry group, Global Alliance for Responsible Media, shut down days after the lawsuit was filed.
Despite these controversies, eMed has expressed confidence in Yaccarino's ability to lead the company. Clare Duffy contributed to this report.
References:
- Business Insider
- Variety
- The Hollywood Reporter
- CNBC
- The New York Times
- In her new role at eMed, Linda Yaccarino intends to apply her expertise in the fields of business, technology, and health-and-wellness, particularly focusing on weight-management and chronic care through digital means, such as GLP-1 drugs like Wegovy and Ozempic.
- As eMed expands its services nationally and globally, Yaccarino's leadership experience in complex markets and her ability to negotiate strategic partnerships will be instrumental in leveraging science and data through digital channels to improve population health management.
